Vertex Pharmaceuticals European Patent for Cancer Treatment Using DNA-Damaging Agents and DNA-PK Inhibitors

The European Patent Office has granted Vertex Pharmaceuticals Incorporated European Patent EP3518931A1, titled 'Method for Treating Cancer Using a Combination of DNA-Damaging Agents and DNA-PK Inhibitors.' The patent covers a therapeutic method combining DNA-damaging agents with DNA-PK (DNA-dependent protein kinase) inhibitors for cancer treatment. Inventors include BouchER, Hillier, Tsai, Hare, Markland, Newsome, and Penney. IPC classifications include A61K 31/506 and C07D 401/14.

The patent provides Vertex Pharmaceuticals with exclusive intellectual property rights covering the combination therapy method across 31 designated European states including Germany, France, the United Kingdom, Italy, Spain, and other EPC contracting states. This grant affects pharmaceutical companies and researchers developing DNA-PK inhibitor-based cancer therapies who may need to consider licensing or design-around strategies before commercializing similar treatments in Europe.